1 材料与方法
1.1 试验材料
1.1.1 主要试剂
1.1.2 仪器设备
1.1.3 样品来源
1.1.4 病原指示菌
1.2 试验方法
1.2.1 菌株分离
1.2.2 分子生物学鉴定
1.2.3 生长曲线测定
1.2.4 产酸能力测定
1.2.5 不同温度下生长曲线测定
1.2.6 对酸的耐受性测定
1.2.7 对胆盐的耐受性测定
1.2.8 对人工胃肠液的耐受性测定
1.2.9 表面疏水性测定
1.2.10 自凝聚性测定
1.2.11 抑菌活性测定
1.2.12 对常见抗生素的敏感性测定
表1 药敏片种类、含药量及抑菌圈直径判定标准Table 1 Types of antibiotic sensitivity discs, drug loading and criteria for judging inhibition zone diameter |
| 抗生素名称 Antibiotics names | 含药量 Drug loading | 抑菌圈直径判断标准 Criteria for judging inhibition zone diameter/mm | ||
|---|---|---|---|---|
| 耐药 Resistance (R) | 中介 Intermediate (I) | 敏感 Sensitive (S) | ||
| 氯霉素Chloramphenicol | 30 μg/片 | ≤12 | 13~17 | ≥18 |
| 红霉素Erythromycin | 15 μg/片 | ≤13 | 14~22 | ≥23 |
| 万古霉素Vancomycin | 30 μg/片 | ≤8 | 9~12 | ≥13 |
| 四环素Tetracycline | 30 μg/片 | ≤14 | 15~18 | ≥19 |
| 克林霉素Clindamycin | 2 μg/片 | ≤13 | 14~17 | ≥18 |
| 庆大霉素Gentamycin | 10 μg/片 | ≤12 | 13~14 | ≥15 |
| 头孢拉定Cefradine | 30 μg/片 | ≤14 | 15~17 | ≥18 |
| 阿奇霉素Azithromycin | 15 μg/片 | ≤10 | 11~15 | ≥16 |
| 环丙沙星Ciprofloxacin | 5 μg/片 | ≤15 | 16~20 | ≥21 |
| 青霉素Penicillin | 10 U/片 | ≤19 | 20~27 | ≥28 |
| 氨苄西林Ampicillin | 10 μg/片 | ≤13 | 14~16 | ≥17 |
| 头孢哌酮Cefoperazone | 75 μg/片 | ≤12 | 13~15 | ≥16 |
1.2.13 非靶向代谢组学分析
1.3 数据统计与分析
2 结果与分析
2.1 瘤胃源酿酒酵母的分离与鉴定
2.2 菌株GRJA008和GRJA012的生长曲线和产酸曲线
2.3 菌株GRJA008和GRJA012的体外益生特性
2.3.1 菌株GRJA008和GRJA012不同温度下的生长曲线
2.3.2 菌株GRJA008和GRJA012对酸的耐受性
2.3.3 菌株GRJA008和GRJA012对胆盐的耐受性
2.3.4 菌株GRJA008和GRJA012对人工胃肠液的耐受性
表2 菌株GRJA008和GRJA012在人工胃液、人工肠液和人工胃肠液中的存活率Table 2 Survival rates of strains GRJA008 and GRJA012 in artificial gastric fluid, artificial intestinal fluid and artificial gastric and intestinal fluids |
| 菌株 Strains | 人工消化液 Artificial digestive fluid | 耐受时间 Tolerance time/h | 活菌数对数值 log10(viable count) | 存活率 Survival rate/% |
|---|---|---|---|---|
GRJA008 | 人工胃液Artificial gastric fluid | 0 | 5.49±0.32 | — |
| 3 | — | |||
人工肠液Artificial intestinal fluid | 0 | 5.78±0.04 | 98.96±1.27 | |
| 3 | 5.72±0.05 | |||
人工胃肠液Artificial gastric and intestinal fluids | 0 | 4.28±0.02 | — | |
| 3 | — | |||
GRJA012 | 人工胃液Artificial gastric fluid | 0 | 5.74±0.04 | — |
| 3 | — | |||
人工肠液Artificial intestinal fluid | 0 | 6.21±0.21 | 95.62±3.25 | |
| 3 | 6.03±0.09 | |||
人工胃肠液Artificial gastric and intestinal fluids | 0 | 4.48±0.01 | 93.85±0.12 | |
| 3 | 4.20±0.00 |
—:因未检测出活菌,无此数据。 | |
—: no data available because no viable bacteria were detected. |
2.3.5 菌株GRJA008和GRJA012的表面疏水性及自凝聚性
表3 菌株GRJA008和GRJA012的表面疏水率及自凝聚率Table 3 Surface hydrophobicity and auto-aggregation rate of strains GRJA008 and GRJA012 % |
| 菌株 Strains | 表面疏水率 Surface hydrophobicity | 自凝聚率 Auto-aggregation rate |
|---|---|---|
| GRJA008 | 89.16±0.32 | 69.93±0.93 |
| GRJA012 | 82.00±0.95 | 91.11±1.06 |
表面疏水性标准设定:表面疏水率在50%以上,为高度疏水;表面疏水率在20%~50%,为中度疏水;表面疏水率在20%以下,为非疏水。自凝聚性标准设定:自凝聚率在16%~35%,为低自凝聚能力;自凝聚率在>35%~50%,为中等自凝聚能力;自凝聚率在50%以上,为高自凝聚能力。 | |
Surface hydrophobicity standards were set as follows: a surface hydrophobicity value above 50% was defined as highly hydrophobic, between 20% to 50% as moderately hydrophobic, and below 20% as non-hydrophobic. Auto-aggregation ability standards were set as follows: an auto-aggregation rate of 16% to 35% was defined as low auto-aggregation ability, >35% to 50% as moderate auto-aggregation ability, and above 50% as high auto-aggregation ability. |
2.3.6 菌株GRJA008和GRJA012的抑菌活性
图6 菌株GRJA008对肠道沙门氏菌(A)、金黄色葡萄球菌(B)的抑菌性能Fig.6 Antibacterial performance of GRJA008 against Salmonella enterica (A) and Staphylococcus aureus (B) |
表4 菌株GRJA008和GRJA012的抑菌活性Table 4 Antibacterial activities of strains GRJA008 and GRJA012 mm |
| 病原指示菌 Indicator pathogenic bacteria | 抑菌圈直径Diameter of inhibition zone | |
|---|---|---|
| GRJA008 | GRJA012 | |
| 肠道沙门氏菌Salmonella enterica | 30.03±1.38 | 无抑菌圈 |
| 金黄色葡萄球菌Staphylococcus aureus | 24.51±1.16 | 无抑菌圈 |
根据抑菌圈直径(D)判定抑菌活性:D≥20 mm,为极敏;15 mm≤D<20 mm,为高敏;10 mm≤D<15 mm,为中敏;0 mm<D<10 mm,为低敏;无抑菌圈,为无抑菌效果。 | |
The antibacterial activity was determined based on the diameter of the inhibition zone (D): D≥20 mm, indicating extremely sensitive; 15 mm≤D<20 mm, indicating highly sensitive; 10 mm≤D<15 mm, indicating moderately sensitive; 0 mm<D<10 mm, indicating low sensitivity; no inhibition zone, indicating no inhibitory effect. |
2.3.7 菌株GRJA008和GRJA012的抗生素敏感性
表5 菌株GRJA008和GRJA012对常见抗生素的敏感性Table 5 Sensitivity of strains GRJA008 and GRJA012 to common antibiotics |
| 抗生素名称 Antibiotics names | 抑菌圈直径 Inhibition zone diameter/mm | 敏感性 Susceptibility | |||
|---|---|---|---|---|---|
| GRJA008 | GRJA012 | GRJA008 | GRJA012 | ||
| 氯霉素Chloramphenicol | 20.71±0.84 | 无抑菌圈 | S | R | |
| 红霉素Erythomycin | 15.98±0.60 | 无抑菌圈 | I | R | |
| 万古霉素Vancomycin | 无抑菌圈 | 无抑菌圈 | R | R | |
| 四环素Tetracycline | 13.29±1.09 | 无抑菌圈 | R | R | |
| 克林霉素Clindamycin | 16.22±1.92 | 无抑菌圈 | I | R | |
| 庆大霉素Gentamycin | 12.77±0.99 | 无抑菌圈 | I | R | |
| 头孢拉定Cefradine | 19.95±0.60 | 无抑菌圈 | S | R | |
| 阿奇霉素Azithromycin | 9.06±0.55 | 无抑菌圈 | R | R | |
| 环丙沙星Ciprofloxacin | 无抑菌圈 | 无抑菌圈 | R | R | |
| 青霉素Penicillin | 13.29±0.98 | 无抑菌圈 | R | R | |
| 氨苄西林Ampicillin | 15.30±0.78 | 无抑菌圈 | I | R | |
| 头孢哌酮Cefoperazone | 20.95±1.07 | 无抑菌圈 | S | R | |
R:耐药 resistance;I:中介 intermediate;S:敏感 sensitive。 |
2.4 菌株GRJA008和GRJA012的代谢特性
2.4.1 代谢组学数据质量评估
图7 非靶向代谢组学数据质量评价A:正离子模式下的总离子流色谱图;B:负离子模式下的总离子流色谱图;C:正离子模式下的质荷比分布图;D:负离子模式下的质荷比分布图;E:正离子模式下的保留时间分布图;F:负离子模式下的保留时间分布图。 Fig.7 Quality evaluation of non-targeted metabolomics data A: total ion chromatogram in positive ion mode; B: total ion chromatogram in negative ion mode; C: m/z distribution in positive ion mode; D: m/z distribution in negative ion mode; E: retention time distribution in positive ion mode; F: retention time distribution in negative ion mode. |
2.4.2 菌株GRJA008和GRJA012的代谢物鉴定
图8 菌株GRJA008(A)和GRJA012(B)代谢物数目排名前20的通路Environmental Information Processing:环境信息处理;Human Diseases:人类疾病;Metabolism:新陈代谢;Organismal Systems:生物体系统;Genetic Information Processing:遗传信息处理;ABC transporters:ABC转运蛋白;Choline metabolism in cancer:癌症中的胆碱代谢;Central carbon metabolism in cancer:癌症中的中心碳代谢;Metabolic pathways:代谢通路;Biosynthesis of secondary metabolites:次生代谢物的生物合成;Microbial metabolism in diverse environments:不同环境中的微生物代谢;Biosynthesis of plant secondary metabolites:植物次生代谢物的生物合成;Linoleic acid metabolism:亚油酸代谢;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid:源自鸟氨酸、赖氨酸和烟酸的生物碱的生物合成;Biosynthesis of amino acids:氨基酸的生物合成;Glycerophospholipid metabolism:甘油磷脂代谢;D-amino acid metabolism:D-氨基酸代谢;2-Oxocarboxylic acid metabolism:2-氧代羧酸代谢;Biosynthesis of phenylpropanoids:苯丙烷类的生物合成;Tropane, piperidine and pyridine alkaloid biosynthesis:莨菪烷、哌啶和吡啶类生物的碱生物合成;Alpha-linolenic acid metabolism:α-亚麻酸代谢;Biosynthesis of alkaloids derived from shikimate pathway:源自莽草酸途径的生物碱的生物合成;Biosynthesis of cofactors:辅因子的生物合成;Biosynthesis of plant hormones:植物激素的生物合成;Protein digestion and absorption:蛋白质消化与吸收;Aminoacyl-tRNA biosynthesis:氨酰-tRNA生物合成;Degradation of aromatic compounds:芳香族化合物的降解;Arachidonic acid metabolism:花生四烯酸代谢。 Fig.8 Top 20 pathways of metabolite numbers of strains GRJA008 (A) and GRJA012 (B) |
表6 菌株GRJA008中甘油磷脂与脂肪酸代谢相关KEGG通路富集情况Table 6 Enrichment of KEGG pathways related to glycerophospholipid and fatty acid metabolism in strain GRJA008 |
| 通路编号 Pathway ID | 通路名称(三级) Pathway name (level 3) | 代谢物数目 Metabolites number | 代表性代谢物 Representative metabolites | ||||
|---|---|---|---|---|---|---|---|
| 591 | 亚油酸代谢 Linoleic acid metabolism | 18 | PC(16∶1(9Z)/18∶1(9Z))、PC(34∶2)、PC(16∶1(9Z)/ 16∶1(9Z))、PC(36∶1)、PC(14∶0/20∶0)、花生四烯酸、 亚油酸、13-羟基十八碳二烯酸、3-氧代十八碳二烯酸、 9-氧代-10E,12Z-十八碳二烯酸、α-翅果酸、9,10-环氧 十八碳单烯酸、12,13-环氧十八碳单烯酸、9(S)-氢过 氧化-10E,12Z-十八碳二烯酸、9,10-二羟基十八碳单烯酸、 12,13-二羟基十八碳单烯酸、8(R)-氢过氧化亚油酸、 9,12,13-三羟基十八碳单烯酸 | ||||
| 564 | 甘油磷脂代谢 Glycerophospholipid metabolism | 15 | 胆碱、PC(16∶1(9Z)/18∶1(9Z))、PC(34∶2)、PC(16∶1 (9Z)/16∶1(9Z))、PC(36∶1)、PC(14∶0/20∶0)、 PE(P-16∶0/22∶6(4Z,7Z,10Z,13Z,16Z,19Z))、 PE(16∶1(9Z)/22∶4(7Z,10Z,13Z,16Z))、甘油磷酸胆碱、 PS(18∶0/18∶1(9Z))、LysoPC(20∶4/0∶0)、LysoPC(16∶0/ 0∶0)、LysoPC(18∶0/0∶0)、LysoPC(20∶1(11Z)/0∶0)、 LysoPC(16∶1/0∶0) | ||||
| 592 | α-亚麻酸代谢 Alpha-linolenic acid metabolism | 11 | PC(16∶1(9Z)/18∶1(9Z))、PC(34∶2)、PC(16∶1 (9Z)/16∶1(9Z))、PC(36∶1)、PC(14∶0/20∶0)、 α-亚麻酸、茉莉酸、亚麻油酸、创伤酸、创伤激素、 乙酸顺式-3-己烯酯 | ||||
| 590 | 花生四烯酸代谢 Arachidonic acid metabolism | 9 | PC(16∶1(9Z)/18∶1(9Z))、PC(34∶2)、 PC(16∶1(9Z)/16∶1(9Z))、PC(36∶1)、 PC(14∶0/20∶0)、花生四烯酸、前列腺素G2、 11-表-前列腺素F2α、6-酮-前列腺素F1α | ||||
| 61 | 脂肪酸的生物合成 Fatty acid biosynthesis | 7 | 棕榈酸、油酸、硬脂酸、月桂酸、肉豆蔻酸、 棕榈烯酸、反式棕榈油酸 | ||||
| 1040 | 不饱和脂肪酸的生物合成 Biosynthesis of unsaturated fatty acids | 6 | 花生四烯酸、棕榈酸、油酸、硬脂酸、 亚油酸、α-亚麻酸 | ||||
| 73 | 角质、木栓质和蜡的生物合成 Cutin, suberine and wax biosynthesis | 4 | 棕榈酸、油酸、(S)-10, 16-二羟基十六烷酸、16-羟基十六烷酸 | ||||
| 71 | 脂肪酸降解 Fatty acid degradation | 1 | 棕榈酸 | ||||
| 62 | 脂肪酸伸长率 Fatty acid elongation | 1 | 棕榈酸 | ||||
| 1212 | 脂肪酸代谢 Fatty acid metabolism | 1 | 棕榈酸 |
表7 菌株GRJA012中胆汁酸与多不饱和脂肪酸代谢相关KEGG通路富集情况Table 7 Enrichment of KEGG pathways related to bile acid and polyunsaturated fatty acid metabolism in strain GRJA012 |
| 通路编号 Pathway ID | 通路名称(三级) Pathway name (level 3) | 代谢物数目 Metabolites number | 代表性代谢物 Representative metabolites |
|---|---|---|---|
| 591 | 亚油酸代谢 Linoleic acid metabolism | 13 | PC(16∶1(9Z)/18∶1(9Z))、PC(16∶1(9Z)/16∶1(9Z))、 PC(34∶2)、PC(14∶0/20∶0)、PC(36∶1)、 花生四烯酸、亚油酸、13-氧代十八碳二烯酸、9-氧代十八 碳二烯酸、α-翅果酸、12,13-环氧十八碳单烯酸、12,13- 二羟基十八碳单烯酸、9,10,13-三羟基十八碳单烯酸 |
| 590 | 花生四烯酸代谢 Arachidonic acid metabolism | 10 | PC(16∶1(9Z)/18∶1(9Z))、PC(16∶1(9Z)/16∶1(9Z))、 PC(34∶2)、PC(14∶0/20∶0)、PC(36∶1)、 花生四烯酸、前列腺素G2、11-表-前列腺素F2α、6- 酮-前列腺素F1α、F2-异前列腺素 |
| 121 | 次级胆汁酸的生物合成 Secondary bile acid biosynthesis | 9 | 胆汁酸、甘胆酸、鹅胆酸、去氧胆酸、牛胆酸、 鹅脱氧胆酸甘氨酸缀合物、胆烷酸、3α,12β-二 羟基-5β-胆烷酸、3β,7α-二羟基-5β-胆烷酸 |
| 592 | α-亚麻酸代谢 Alpha-linolenic acid metabolism | 9 | PC(16∶1(9Z)/18∶1(9Z))、PC(16∶1(9Z)/ 16∶1(9Z))、PC(34∶2)、PC(14∶0/20∶0)、PC(36∶1)、 α-亚麻酸、亚麻油酸、创伤酸、乙酸顺式-3-己烯酯 |
| 1040 | 不饱和脂肪酸的生物合成 Biosynthesis of unsaturated fatty acids | 7 | 花生四烯酸、棕榈酸、油酸、硬脂酸、 亚油酸、α-亚麻酸、芥子酸 |
| 120 | 初级胆汁酸的生物合成 Primary bile acid biosynthesis | 5 | 胆汁酸、甘胆酸、鹅胆酸、牛胆酸、 鹅脱氧胆酸甘氨酸缀合物 |
2.4.3 组间PLS-DA
2.4.4 菌株GRJA008和GRJA012的差异代谢物鉴定和KEGG功能富集分析
图10 差异代谢物火山图(A)和KEGG富集通路图(B)Linoleic acid metabolism:亚油酸代谢;ABC transporters:ABC转运蛋白;Biosynthesis of plant secondary metabolites:植物次生代谢物的生物合成;Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid:源自鸟氨酸、赖氨酸和烟酸的生物碱的生物合成;Alpha-linolenic acid metabolism:α-亚麻酸代谢;Efferocytosis:胞葬作用;D-amino acid metabolism:D-氨基酸代谢;Secondary bile acid biosynthesis:次级胆汁酸的生物合成;Cholesterol metabolism:胆固醇代谢;Choline metabolism in cancer:癌症中的胆碱代谢;Primary bile acid biosynthesis:初级胆汁酸的生物合成;Protein digestion and absorption:蛋白质消化与吸收;Bile secretion:胆汁分泌;Glycerophospholipid metabolism:甘油磷脂代谢;Retrograde endocannabinoid signaling pathway:逆行内源性大麻素信号通路;Aldosterone synthesis and secretion:醛固酮合成与分泌;Arginine biosynthesis:精氨酸的生物合成;Biosynthesis of plant hormones:植物激素的生物合成;Tropane, piperidine and pyridine alkaloid biosynthesis:莨菪烷、哌啶和吡啶类生物碱的生物合成;Chemical carcinogenesis-receptor activation:化学致癌-受体激活;Pathways in cancer:癌症通路;Renal cell carcinoma:肾细胞癌;Breast cancer:乳腺癌;Autophagy-yeast:自噬-酵母;Autophagy-other:自噬-其他;Pathogenic Escherichia coli infection:致病性大肠杆菌感染;mTOR signaling pathway:mTOR信号通路;Oocyte meiosis:卵母细胞减数分裂。 Fig.10 Volcano plot of differential metabolites (A) and KEGG enrichment pathway diagram (B) |
表8 正离子模式下菌株GRJA008和GRJA012间的差异代谢物(前20)Table 8 Differential metabolites between strains GRJA008 and GRJA012 in positive ion mode (top 20) |
| 差异代谢物 Differential metabolites | 变量投影重要性 VIP | 调节 Regulated | P值 P-value | ||||
|---|---|---|---|---|---|---|---|
| 甲氧基丁香酚Methoxyeugenol | 1.24 | ↑ | 0.026 | ||||
| 1,1'-[1,12-十二烷二基双(氧)]双苯 1,1'-[1,12-dodecanediylbis(oxy)]bisbenzene | 1.11 | ↑ | 0.016 | ||||
| 4-甲氧基苯甲醛4-methoxybenzaldehyde | 1.16 | ↓ | 0.011 | ||||
| 荜茇明碱Piplartine | 1.30 | ↓ | 0.009 | ||||
| 孕酮Progesterone | 1.29 | ↓ | 0.007 | ||||
| 7-甲氧基-2-甲基异黄酮 7-methoxy-2-methylisoflavone | 1.16 | ↓ | 0.005 | ||||
| 3-(3,4,5-三甲氧基苯基)丙酸 3-(3,4,5-trimethoxyphenyl)propanoic acid | 1.00 | ↑ | 0.005 | ||||
| 4-(乙氧基甲基)-2-甲氧基苯酚 4-(ethoxymethyl)-2-methoxyphenol | 3.09 | ↓ | 4.26E-03 | ||||
| 溶血磷脂酰乙醇胺(0∶0/20∶4(5Z,8Z,11Z,14Z)) LysoPE(0∶0/20∶4(5Z,8Z,11Z,14Z)) | 3.05 | ↑ | 3.92E-03 | ||||
| 甘氨脱氧胆酸Glycoursodeoxycholic acid | 3.04 | ↑ | 3.68E-03 | ||||
| 2-呋喃甲酸戊酯Amyl 2-furoate | 2.97 | ↓ | 3.62E-03 | ||||
| 法卡林二酮Falcarindione | 2.92 | ↓ | 3.23E-03 | ||||
| 5-羟基-2-(5-甲基-1-氧代-4-己烯基)苯并呋喃 5-hydroxy-2-(5-methyl-1-oxo-4-hexenyl)benzofuran | 2.88 | ↓ | 3.20E-03 | ||||
| 溶血磷脂酰胆碱(17∶0/0∶0) LysoPC(17∶0/0∶0) | 2.70 | ↑ | 2.99E-03 | ||||
| 溶血磷脂酰乙醇胺(20∶1(11Z)/0∶0)LysoPE(20∶1(11Z)/0∶0) | 2.42 | ↑ | 2.67E-03 | ||||
| 胆甾-4,6-二烯-3-酮Cholesta-4,6-dien-3-one | 2.40 | ↑ | 1.55E-03 | ||||
| N-甲氧羰基-N-去甲荷叶碱N-methoxycarbonyl-N-nornuciferine | 1.86 | ↓ | 1.52E-03 | ||||
| 2-(2-甲基丙氧基)萘2-(2-methylpropoxy)naphthalene | 1.75 | ↓ | 1.40E-03 | ||||
| 4-(丁氧基甲基)-2-甲氧基苯酚4-(butoxymethyl)-2-methoxyphenol | 1.05 | ↓ | 1.37E-03 | ||||
| 胆酸Cholic acid | 1.41 | ↑ | 1.28E-03 |
表9 负离子模式下菌株GRJA008和GRJA012间的差异代谢物(前20)Table 9 Differential metabolites between strains GRJA008 and GRJA012 in negative ion mode (top 20) |
| 差异代谢物 Differential metabolites | 变量投影重要性 VIP | 调节 Regulated | P值 P-value |
|---|---|---|---|
| 4-羟基丁酸4-hydroxybutyric acid | 1.01 | ↓ | 0.030 |
| 脑羟脂酸Cerebronic acid | 1.02 | ↑ | 0.021 |
| 刺桐酚素Cristacarpin | 1.19 | ↑ | 0.010 |
| 吐叶醇-9-[木糖基-(1→6)-葡萄糖苷] Vomifoliol 9-[xylosyl-(1→6)-glucoside] | 1.05 | ↓ | 0.008 |
| 2-羟基肉豆蔻酸2-hydroxymyristic acid | 1.02 | ↓ | 0.006 |
| 5-己基四氢-2-呋喃辛酸5-hexyltetrahydro-2-furanoctanoic acid | 1.28 | ↓ | 0.006 |
| 磷脂酰乙醇胺(20∶4(5Z,8Z,11Z,14Z)/18∶1(11Z)) PE(20∶4(5Z,8Z,11Z,14Z)/18∶1(11Z)) | 2.04 | ↓ | 0.005 |
| 创伤酸Traumatic acid | 1.98 | ↓ | 0.004 |
| 安诺切林A Annocherin A | 1.02 | ↓ | 0.003 |
| 鳄梨烯醇2-乙酸酯Avocadene 2-acetate | 1.10 | ↑ | 0.003 |
| 4-羟基-(3',4'-二羟基苯基)戊酸 4-hydroxy-(3',4'-dihydroxyphenyl)-valeric acid | 1.26 | ↑ | 0.003 |
| 磷脂酰肌醇(18∶0/18∶2(9Z,12Z)) PI(18∶0/18∶2(9Z,12Z)) | 1.65 | ↓ | 0.003 |
| 利卡林C Licarin C | 1.02 | ↓ | 0.002 |
| 滨蒿内酯Scoparone | 1.16 | ↑ | 0.002 |
| D6-黄葵内酯D6-ambrettolide | 1.27 | ↑ | 0.001 |
| 4,5-二氢荜茇明宁碱4,5-dihydropiperlonguminine | 1.13 | ↓ | 0.001 |
| 1-甲氧基-1H-吲哚-3-羧酸甲酯 Methyl 1-methoxy-1H-indole-3-carboxylate | 3.30 | ↓ | 0.001 |
| 15-乙酰氧基疣孢青霉烯-3,4-二醇4-O-α-D-吡喃葡萄糖苷 15-acetoxyscirpene-3,4-diol 4-O-a-D-glucopyranoside | 1.00 | ↓ | 8.01E-04 |
| 10-氧代-11-十八碳烯-13-交酯10-oxo-11-octadecen-13-olide | 1.18 | ↑ | 7.05E-04 |
| 烟酸Nicotinic acid | 1.22 | ↓ | 6.76E-04 |
2.4.5 菌株GRJA008和GRJA012的差异代谢物相关性热图与网络图分析
图11 差异代谢物相关性热图(A)与网络图(B)Cerebronic acid:脑羟脂酸;LysoPE(20∶1(11Z)/0∶0):溶血磷脂酰乙醇胺(20∶1(11Z)/0∶0);LysoPC(17∶0/0∶0):溶血磷脂酰胆碱(17∶0/0∶0);Avocadene 2-acetate:鳄梨烯2-乙酸酯;Cristacarpin:刺桐酚素;Cholesta-4,6-dien-3-one:胆甾-4,6-二烯-3-酮;LysoPE(0∶0/20∶4(5Z,8Z,11Z,14Z)):溶血磷脂酰乙醇胺(0∶0/20∶4(5Z,8Z,11Z,14Z));Methoxyeugenol:甲氧基丁香酚;Glycoursodeoxycholic acid:甘氨脱氧胆酸;Cholic acid:胆酸;4-Hydroxy-(3',4'-dihydroxyphenyl)-valeric acid:4-羟基-(3',4'-二羟基苯基)-戊酸;4-Hydroxybutyric acid:4-羟基丁酸;2-Hydroxymyristic acid:2-羟基肉豆蔻酸;15-Acetoxyscirpene-3,4-diol 4-O-a-D-glucopyranoside:15-乙酰氧基疣孢青霉烯-3,4-二醇4-O-α-D-葡萄糖吡喃苷;Annocherin A:安诺切林A;4-Methoxybenzaldehyde:4-甲氧基苯甲醛;PE(20∶4(5Z,8Z,11Z,14Z)/18∶1(11Z)):磷脂酰乙醇胺(20∶4(5Z,8Z,11Z,14Z)/18∶1(11Z));Methyl 1-methoxy-1H-indole-3-carboxylate:1-甲氧基-1H-吲哚-3-羧酸甲酯;Traumatic acid:创伤酸;Nicotinic acid:烟酸;5-Hexyltetrahydro-2-furanoctanoic acid:5-己基四氢-2-呋喃辛酸;Vomifoliol 9-[xylosyl-(1→6)-glucoside]:呕吐醇9-[木糖基-(1→6)-葡萄糖苷];4-(Ethoxymethyl)-2-methoxyphenol:4-(乙氧甲基)-2-甲氧基苯酚;7-Methoxy-2-methylisoflavone:7-甲氧基-2-甲基异黄酮;4-(Butoxymethyl)-2-methoxyphenol:4-(丁氧甲基)-2-甲氧基苯酚;Falcarindione:法卡林二酮;Amyl 2-furoate:2-呋喃甲酸戊酯;PI(18∶0/18∶2(9Z,12Z)):磷脂酰肌醇(18∶0/18∶2(9Z,12Z));Progesterone:孕酮;2,2,4-Trimethyl-1,3-dioxolane:2,2,4-三甲基-1,3-二氧戊烷;2-Hexyl-5-[2-(4-hydroxy-3-methoxyphenyl)ethyl]furan:2-己基-5-[2-(4-羟基-3-甲氧基苯基)乙基]呋喃;2'-Hydroxy-4',6'-dimethoxy-3'-methylacetophenone:2'-羟基-4',6'-二甲氧基-3'-甲基苯乙酮;3-Oxododecanoic acid:3-氧代十二烷酸;4-Hydroxy-2,6,6-trimethyl-3-oxo-1,4-cyclohexadiene-1-carboxaldehyde:4-羟基-2,6,6-三甲基-3-氧代-1,4-环己二烯-1-甲醛;4-Methoxybenzyl O-(2-sulfoglucoside):4-甲氧基苄基O-(2-磺酰葡萄糖苷);Alpha-terpinyl anthranilate:α-松油基邻氨基苯甲酸酯;Bisphenol A:双酚A;Dipropyl hexanedioate:己二酸二丙酯;D-malic acid:D-苹果酸;Glyceollin Ⅲ:甘油醇Ⅲ;Glycocholic acid:甘胆酸;LysoPC(18∶0/0∶0):溶血磷脂酰胆碱(18∶0/0∶0);LysoPC(20∶1(11Z)/0∶0):溶血磷脂酰胆碱(20∶1(11Z)/0∶0);Methyl 1-methoxy-1H-indole-3-carboxylate:甲基1-甲氧基-1H-吲哚-3-甲酸甲酯;N-acetylhistidine:N-乙酰组氨酸;Octanoylcarnitine:辛酰肉碱;Oxalic acid dibutyl ester:草酸二丁酯;Phenylethylamine:苯乙胺;Retinol acetate:乙酸视黄醇;Stanozolol:司坦唑醇;Trehalose:海藻糖;xi-2,3-Dihydro-2-oxo-1H-indole-3-acetic acid:xi-2,3-二氢-2-氧代-1H-吲哚-3-乙酸;z-Clausenamide:z-黄皮酰胺。 Fig.11 Heatmap (A) and network diagram (B) of differential metabolite correlations |

京公网安备 11010802041926号